PMID- 30642006
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 1
DP  - 2019 Jan 11
TI  - Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical 
      Overview.
LID - 10.3390/cancers11010082 [doi]
LID - 82
AB  - Proteins of the mammalian target of rapamycin (mTOR) signaling axis are 
      overexpressed or mutated in cancers. However, clinical inhibition of mTOR 
      signaling as a therapeutic strategy in oncology shows rather limited progress. 
      Nanoparticle-based mTOR targeted therapy proposes an attractive therapeutic 
      option for various types of cancers. Along with the progress in the biomedical 
      applications of nanoparticles, we start to realize the challenges and 
      opportunities that lie ahead. Here, we critically analyze the current literature 
      on the modulation of mTOR activity by nanoparticles, demonstrate the complexity 
      of cellular responses to functionalized nanoparticles, and underline challenges 
      lying in the identification of the molecular mechanisms of mTOR signaling 
      affected by nanoparticles. We propose the idea that subcytotoxic doses of 
      nanoparticles could be relevant for the induction of subcellular structural 
      changes with possible involvement of mTORC1 signaling. The evaluation of the 
      mechanisms and therapeutic effects of nanoparticle-based mTOR modulation will 
      provide fundamental knowledge which could help in developing safe and efficient 
      nano-therapeutics.
FAU - Lunova, Mariia
AU  - Lunova M
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. mariialunova@googlemail.com.
AD  - Institute for Clinical & Experimental Medicine (IKEM), Prague, 140 21, Czech 
      Republic. mariialunova@googlemail.com.
FAU - Smolkova, Barbora
AU  - Smolkova B
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. smolkova@fzu.cz.
FAU - Lynnyk, Anna
AU  - Lynnyk A
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. lynnyk@fzu.cz.
FAU - Uzhytchak, Mariia
AU  - Uzhytchak M
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. uzhytchak@fzu.cz.
FAU - Jirsa, Milan
AU  - Jirsa M
AD  - Institute for Clinical & Experimental Medicine (IKEM), Prague, 140 21, Czech 
      Republic. miji@ikem.cz.
FAU - Kubinova, Sarka
AU  - Kubinova S
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. sarka.k@biomed.cas.cz.
AD  - Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, 
      14220, Czech Republic. sarka.k@biomed.cas.cz.
FAU - Dejneka, Alexandr
AU  - Dejneka A
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. dejneka@fzu.cz.
FAU - Lunov, Oleg
AU  - Lunov O
AUID- ORCID: 0000-0003-2922-8896
AD  - Institute of Physics of the Czech Academy of Sciences, Prague, 18221, Czech 
      Republic. lunov@fzu.cz.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190111
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6356373
OTO - NOTNLM
OT  - lysosomes
OT  - mTOR
OT  - molecular targeting
OT  - nanoparticles
OT  - reactive oxygen species
COIS- The authors declare no conflict of interest.
EDAT- 2019/01/16 06:00
MHDA- 2019/01/16 06:01
PMCR- 2019/01/11
CRDT- 2019/01/16 06:00
PHST- 2018/11/22 00:00 [received]
PHST- 2018/12/21 00:00 [revised]
PHST- 2019/01/05 00:00 [accepted]
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/01/16 06:01 [medline]
PHST- 2019/01/11 00:00 [pmc-release]
AID - cancers11010082 [pii]
AID - cancers-11-00082 [pii]
AID - 10.3390/cancers11010082 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Jan 11;11(1):82. doi: 10.3390/cancers11010082.